Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc. (VRCA): 5 pipeline candidates · 4 upcoming catalysts · ~8 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
8.1 months
D/E 1.42 · 24% dilution
Lead: Approved
5 candidates
4 upcoming, next in ~348d
N/A
A transparent, data-derived signal for Verrica Pharmaceuticals Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$100.2M
Cash
$20.9M
Quarterly Burn
$9.2M
Runway
8.1 mo
Revenue
$5.0M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (5 candidates)
Upcoming Catalysts (4)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
38
Total value held
$23.8M
| Holder | Shares | Value |
|---|---|---|
| caligan partners lp | 923,910 | $4.9M |
| affinity asset advisors, llc | 707,338 | $3.7M |
| cannell capital llc | 685,123 | $3.6M |
| armistice capital, llc | 518,181 | $2.7M |
| vanguard capital management llc | 377,516 | $2.0M |
| boothbay fund management, llc | 280,734 | $1.5M |
| dafna capital management llc | 153,712 | $813K |
| marshall wace, llp | 140,497 | $743K |
| geode capital management, llc | 138,917 | $735K |
| stonepine capital management, llc | 99,735 | $528K |
Showing top 10 of 38 institutional holders of Verrica Pharmaceuticals Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Verrica Pharmaceuticals Inc.'s pipeline?
Verrica Pharmaceuticals Inc. (VRCA) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Verrica Pharmaceuticals Inc.'s lead drug candidate?
Verrica Pharmaceuticals Inc.'s most advanced tracked candidate is dsuvia (Approved) for 1 INDICATIONS AND USAGE DSUVIA is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use: Not for home use or for use in children. Discontinue treatment with DSUVIA before patients leave the certified medically supervised healthcare setting. Not for use for.
What is Verrica Pharmaceuticals Inc.'s next catalyst?
Verrica Pharmaceuticals Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: COVE-2: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and S" — expected June 1, 2027.
What is Verrica Pharmaceuticals Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Verrica Pharmaceuticals Inc. has approximately 8.1 months of cash runway.
What is Verrica Pharmaceuticals Inc.'s market capitalization?
Verrica Pharmaceuticals Inc.'s market capitalization is approximately $100.2M.
Get the full picture on Verrica Pharmaceuticals Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.